Trials / Completed
CompletedNCT02333383
Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients
A Prospective, Mono-Country, Multi-Center Study to Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis Patients on Adalimumab Therapy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 201 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 19 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This was a prospective mono-country, multi-center study of the frequency of extra-axial manifestations (EAMs) in Ankylosing Spondylitis (AS) participants treated with adalimumab in routine clinical practice.
Detailed description
A baseline assessment was performed prior to the first dose of adalimumab. Participants received 40 mg of adalimumab every other week for one year. Study visits were conducted at 12, 28, 36 and 52 weeks. All participants were to have one follow-up approximately 70 days after the last dose of adalimumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adalimumab | Adalimumab pre-filled syringe, administered by subcutaneous injection |
Timeline
- Start date
- 2014-12-31
- Primary completion
- 2017-08-08
- Completion
- 2017-08-08
- First posted
- 2015-01-07
- Last updated
- 2019-01-15
- Results posted
- 2019-01-15
Source: ClinicalTrials.gov record NCT02333383. Inclusion in this directory is not an endorsement.